A highly conserved WDYPKCDRA epitope in the RNA directed RNA polymerase of human coronaviruses can be used as epitope-based universal vaccine design

BMC Bioinformatics

Refat Sharmin¹  Abul Bashar Mir Md Khademul Islam¹ 

[1] Department of Genetic Engineering and Biotechnology, University of Dhaka, Science Complex Building, Dhaka 1000, Bangladesh

关键词: Universal vaccine;    Epitope;    RNA directed RNA polymerase;    MERS-CoV;    SARS-CoV;    Coronavirus;   

Others  :  818525
DOI  :  10.1186/1471-2105-15-161

 received in 2014-02-12, accepted in 2014-05-19,  发布年份 2014

【 摘 要 】

Background

Coronaviruses are the diverse group of RNA virus. From 1960, six strains of human coronaviruses have emerged that includes SARS-CoV and the recent infection by deadly MERS-CoV which is now going to cause another outbreak. Prevention of these viruses is urgent and a universal vaccine for all strain could be a promising solution in this circumstance. In this study we aimed to design an epitope based vaccine against all strain of human coronavirus.

Results

Multiple sequence alignment (MSA) approach was employed among spike (S), membrane (M), enveloped (E) and nucleocapsid (N) protein and replicase polyprotein 1ab to identify which one is highly conserve in all coronaviruses strains. Next, we use various in silico tools to predict consensus immunogenic and conserved peptide. We found that conserved region is present only in the RNA directed RNA polymerase protein. In this protein we identified one epitope WDYPKCDRA is highly immunogenic and 100% conserved among all available human coronavirus strains.

Conclusions

Here we suggest in vivo study of our identified novel peptide antigen in RNA directed RNA polymerase protein for universal vaccine – which may be the way to prevent all human coronavirus disease.

【 授权许可】

   
2014 Sharmin and Islam; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Luis E, Isabel S, Sonia Z, Fernando A: Coronavirus Replication and Interaction with Host. In Animal Viruses: Molecular Biology. UK: Caister Academic Press; 2008:149-202.
• [2]De Groot RJ, Baker SC, Baric R, Enjuanes L, Gorbalenya AE, Holmes KV, Perlman S, Poon L, Rottier PJM, Talbot PJ, Woo PCY, Ziebuhr J: Family Coronaviridae. In International Committee on Taxonomy of Viruses. (ninth report). Oxford: Elsevier; 2011:806-828.
• [3]Lu R, Yu X, Wang W, Duan X, Zhang L, Roujian L, Xiaoyan Y, Wen W, Xijie D, Linglin Z, Weimin Z, Jin X, Lingjie X, Qin H, Jianxin L, Li R, Zhong W, Wenjie T: Characterization of human coronavirus etiology in Chinese adults with acute upper respiratory tract infection by real-timeRT-PCR assays. PLoS One 2012, 7(6):e38638.
• [4]Global alert and response (GAR): Middle East respiratory syndrome coronavirus (MERS-CoV) – update. World Health Organization; 2014. [http://www.who.int/csr/don/2014_01_09/en/ webcite]
• [5]Boheemen S, Sander B, Miranda G, Chris L, Theo MB, Stalin R, Ali MZ, Albert DME, Bart LH, Osterhaus AD, Alexander EG, Eric JS, Ron AMF: Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 2012, 3(6):e00473-12.
• [6]Wever BA, Van der Hoek L: Recently discovered human coronaviruses. Clin Lab Med 2009, 29(4):715-724.
• [7]Chan-Yeung M, Xu RH: SARS: epidemiology. Respirology 2003, 8:S9-S14.
• [8]Hofmann H, Pyrc K, Van der Hoek L, Geier M, Ben B, Stefan P: Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 2005, 102(22):7988-7993.
• [9]Ali Mohamed Z, Van Boheemen S, Bestebroer TM, Albert DME, Osterhaus AD, Ron AM, Fouchier RA: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814.
• [10]Sørensen MD, Sørensen B, Gonzalez-Dosal R, Melchjorsen CJ, Weibel J, Wang J, Jun CW, Huanming Y, Kristensen P: Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals. Ann N Y Acad Sci 2006, 1067:500-505. PMID 16804033
• [11]Cheng VC, Lau SK, Woo PC, Yuen KY: Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007, 20:660e94.
• [12]Pierre S: First coronavirus sufferer in France dies in hospital Reuters. 2013. [http://uk.reuters.com/article/2013/05/28/uk-coronavirus-france-idUKBRE94R0Y320130528 webcite]
• [13]Robert R: Coronavirus cases, deaths reported in Tunisia, Saudi Arabia. 2013. [http://www.cidrap.umn.edu/news-perspective/2013/05/coronavirus-cases-deaths-reported-tunisia-saudi-arabia webcite]
• [14]Helen B: Spain reports its first MERS case; woman travelled to Saudi Arabia for Hajj. 2013. [http://www.vancouversun.com/health/Spain+reports+first+MERS+case+woman+travelled+Saudi+Arabia+Hajj/9133754/story.html webcite]
• [15]Middle East respiratory syndrome coronavirus (MERS-CoV) 2014. [http://www.cdc.gov/coronavirus/MERS/faq.html webcite]
• [16]Falzarano D, Darryl F, De Emmie W, Cynthia M, Julie C, Vincent J, Heinz F, Munster VJ: Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci Rep 2013, 3:1686.
• [17]Wong SS, Yuen KY: The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2008, 62:437-441.
• [18]Coronavirus [http://www.cdc.gov/coronavirus/about/index.html webcite]
• [19]Xianfu W, Smith TG, Rupprecht CE: From brain passage to cell adaptation: the road of human rabies vaccine development. Exper Rev Vaccines 2011, 10(11):1597-1608.
• [20]Plotkin SA: Vaccines: Past, present and future. Nat Med 2005, 11(4):S5-S11.
• [21]Matthew C, Lam TT, Watson SJ, Annie LP, Velilava P, Paul G, Oliver GP, Andrew R, Yi G, Deenan P, Paul K, Eleni K: Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis 2013, 19:5.
• [22]Islam R, Sadman S, Aubhishek Z: A computational assay to design an epitope-based peptide vaccine against Chikungunya virus. Future Virol 2012, 7(10):1029-1042.
• [23]Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994, 22(22):4673-4680.
• [24]Garcia-Boronat M, Diez-Rivero CM, Reinherz EL, Pedro AR: PVS: a web server for protein sequence variability analysis tuned to facilitate conserved epitope discovery. Nucleic Acids Res 2008, 36(Web Server issue):W35-W41.
• [25]Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ: Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009, 25:1189-1191.
• [26]Caoili SEC: B-cell epitope prediction for peptide-based vaccine design: towards a paradigm of biological outcomes for global health. Immunome Res 2011, 7:2. 2
• [27]Kolaskar A, Tongaonkar PC: A semiempirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 1990, 276(1):172-174.
• [28]Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, Damle R, Sette A, Peters B: The immune epitope database 2.0. Nucleic Acids Res 2010, 38(Database issue):D854-D862.
• [29]Jens Erik PL, Pontoppidan L, Ole L, Morten N: Improved method for predicting linear B-cell epitopes. Immunome Res 2006, 2:2. BioMed Central Full Text
• [30]Emini EA, Hughes JV, Perlow DS, Boger J: Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 1985, 55(3):836-839.
• [31]Bui HH, Sidney J, Li W, Fusseder N, Sette A: Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 2007, 8(1):361. PMID: 17897458 BioMed Central Full Text
• [32]Parker JM, Guo D, Hodges RS: New hydrophilicity scale derived from high performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 1986, 23:25.
• [33]Zhang Y: I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008, 9:40. BioMed Central Full Text
• [34]Laskowski RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a program to check the stereochemical qualit of protein structures. J Appl Cryst 2001, 26:283-291.
• [35]Pettersen EF, Goddard TD, Huang CC: UCSF Chimera- a visualization system for exploratory research and analysis. J Comput Chem 2004, 25:1605-1612.
• [36]To KKW, Hung IFN, Chan JFW, Yuen KY: From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis 2013, 5((Suppl 2)):S103-S108.
• [37]Muller MA, Muller MA, Stalin RV, Doreen M, Benjamin M, Stephan K, Saskia L, Robert W, Sabine S, Tasnim S, Katrin Z, Tabea B, Isabella E, Marco T, Ali MZ, Albert DME, Ron AM, Bart LH, Christian D: Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines. mBio 2012, 3:e00515-12.
• [38]Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ: A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428(6982):561-564.
• [39]Sudhakar A, Robin G, Boyd L, Agnihothram S, Gopal R, Yount BL Jr, Donaldson EF, Menachery VD, Graham RL, Scobey TD, Gralinski LE, Denison MR, Zambon M, Baric R: Platform strategies for rapid response against emerging coronaviruses: MERS-CoV serologic and antigenic relationships in vaccine design. J Infect Dis 2013, 10:1093.
• [40]Fernando A, Marta L, Isabel S, Sonia Z, Jose L, Silvia LJ, German A, Luis E: Engineering a replication-competent, propagation defective middle east respiratory syndrome coronavirus as a vaccine candidate. mBio 2013, 4(5):e00650-13.
• [41]Pica N, Palese P: Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013, 64:189-202.
• [42]Elaine VJ, Sharon K, Timothy JM, Albert PR, Smithkline BC: Universal coronavirus vaccine. WIPO Patentscope 1993. WO1993023421 A1. [http://www.google.com/patents/WO1993023421A1?cl=en webcite]
• [43]Arnon R: A novel approach to vaccine design–epitope-based vaccines. FEBS J 2006, 273:33-34.
• [44]Olesen OF, Lonnoroth A, Mulligan B: Human vaccine research in the European Union. Vaccine 2009, 27(5):640-645.
• [45]Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW: GenBank. Nucleic Acids Res 2008, 41(Database issue):D36-D42.